These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12875482)

  • 1. Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophy.
    Rosei EA
    Blood Press; 2003; 12(3):183-4. PubMed ID: 12875482
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypertensive heart disease.
    Diamond JA; Phillips RA
    Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive approach to target organ damage in hypertensive women.
    Modena MG; Rossi R
    J Hypertens Suppl; 2002 May; 20(2):S66-9. PubMed ID: 12183857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular hypertrophy in the dialysed patient. What can be done about it?
    Cannella G
    Nephrol Dial Transplant; 1996 Mar; 11(3):418-20. PubMed ID: 8671807
    [No Abstract]   [Full Text] [Related]  

  • 5. Ventricular repolarization in hypertension: beyond Bazett.
    Passino C; Emdin M
    Am J Hypertens; 2008 Jan; 21(1):9. PubMed ID: 18091736
    [No Abstract]   [Full Text] [Related]  

  • 6. Procollagen type I carboxy-terminal peptide shows left ventricular hypertrophy and diastolic dysfunction in hypertensive patients.
    Demir M; Acartürk E; Inal T; Attila G; Dönmez Y; Avkaroğullari M; Cayli M
    Cardiovasc Pathol; 2007; 16(2):69-74. PubMed ID: 17317538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophy.
    Rosei EA
    J Hypertens; 2001 Dec; 19(12):2288-90. PubMed ID: 11725178
    [No Abstract]   [Full Text] [Related]  

  • 8. Reducing hypertension-associated cardiorenal risk: the role of heart rate, left ventricular hypertrophy regression, and renoprotection.
    Materson BJ
    Am J Hypertens; 1999 Jan; 12(1 Pt 2):1S-2S. PubMed ID: 10077412
    [No Abstract]   [Full Text] [Related]  

  • 9. [The goal of antihypertensive therapy: preventing left heart dysfunction].
    Motz W
    MMW Fortschr Med; 1999 Aug; 141(33):39-40. PubMed ID: 10726128
    [No Abstract]   [Full Text] [Related]  

  • 10. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension.
    Stergiou GS; Argyraki KK; Moyssakis I; Mastorantonakis SE; Achimastos AD; Karamanos VG; Roussias LG
    Am J Hypertens; 2007 Jun; 20(6):616-21. PubMed ID: 17531917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular hypertrophy and hypertension.
    Katibi IA
    Niger J Med; 2004; 13(1):8-17. PubMed ID: 15296101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Left ventricular myocardial hypertrophy in arterial hypertension: clinical significance, diagnosis, effects of antihypertensive drugs].
    Martynov AI; Ostroumova OD; Mataev VI; Gedgafpva SIu; Il'ina SV
    Klin Med (Mosk); 2000; 78(10):10-7. PubMed ID: 11220891
    [No Abstract]   [Full Text] [Related]  

  • 14. The aging hypertensive heart: a brief update.
    Susic D; Frohlich ED
    Nat Clin Pract Cardiovasc Med; 2008 Feb; 5(2):104-10. PubMed ID: 18223542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and the heart.
    Mancia G; Scopelliti F; Grassi G
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):198-202. PubMed ID: 16959750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderately elevated blood pressure. A report from SBU, The Swedish Council on Technology Assessment in Health Care.
    J Intern Med; 1995; 238 Suppl 737():1-225. PubMed ID: 9422043
    [No Abstract]   [Full Text] [Related]  

  • 18. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Wachtell K; Papademetriou V; Smith G; Gerdts E; Dahlöf B; Engblom E; Aurigemma GP; Bella JN; Ibsen H; Rokkedal J; Devereux RB
    Am Heart J; 2004 Sep; 148(3):538-44. PubMed ID: 15389245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in structure and function of the left ventricle in the hypertension syndrome.
    Papademetriou V; Kokkinos PF
    J Cardiovasc Risk; 1997 Aug; 4(4):261-5. PubMed ID: 9477203
    [No Abstract]   [Full Text] [Related]  

  • 20. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle.
    Cha YM; Redfield MM; Shen WK; Gersh BJ
    Circulation; 2004 Jun; 109(23):2839-43. PubMed ID: 15197156
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.